超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

德國Responsif
Responsif 在癌癥疫苗應用和傳染性疾病疫苗研發領域提供其獨家專有納米級輸運技術－NanosVir? 輸運技術。
NanosVir? 輸運技術的兩大表現方式是：(i) 分別包含外殼蛋白、次要外殼蛋白VP1、VP2/VP3和用于蛋白質包埋的鼠類多瘤病毒的蛋白質類納米顆粒（非感染性、不能復制、無濾過性毒菌DNA 的病毒式顆粒）和(ii) 供蛋白質/ 縮氨酸在微粒表面排列使用的單獨VP1 類納米結構載體。
在研發應用的基礎上，這些納米顆粒在酵母、大腸桿菌里以再結合方式顯現出來。納米微粒結構的制造工藝可升級、轉移到環磷酸鳥苷生產設備。對于探索性項目，Responsif 可與客戶簽署付費服務合同，根據客戶需要，為蛋白質/ 縮氨酸/ 多抗原決定基實體提供NanosVir? 輸運技術。
鑒于我們擁有NanosVir? 輸運技術的知識產權，我們可以與用戶簽署合同，建立長期業務模式（如：以專利權稅為基礎的模式或成立合資公司）。

With its NanosVir? delivery technology responsif offers exclusive and proprietary
nanoparticular delivery technologies for application in the field of cancer vaccines (main
activities) and in the area of vaccine development against infectious diseases.
The two main NanosVir? delivery technologies represent (i) protein-based nanoparticles
(non-infectious, non-replicating virus-like-particles w/o viral DNA) consisting of the major
and minor coat proteins VP1 and VP2/VP3, respectively, of murine polyomavirus for protein
encapsulation and (ii) solely VP1-based nanostructured carriers for protein/peptide display on
the particle surface.
Depending on the field of R&D application these nanoparticles are recombinantly expressed
in yeast or in Escherichia coli. The manufacturing process for the nanoparticulate structures
is scalable and transferable to cGMP production facilities. For exploratory projects responsif
may initially offer fee-for-service contracts for NanosVir? delivery of customer-specific
protein/peptide/multi-epitope entities. Based on our strong intellectual property position for
the NanosVir? technology such contract can be extended to long-term business models (e.g.
royalty-based models or joint-ventures).